Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MNPR - US61023L2079 - Common Stock

69.6 USD
+2.56 (+3.82%)
Last: 1/14/2026, 8:00:01 PM
69.6 USD
0 (0%)
After Hours: 1/14/2026, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNPR. MNPR was compared to 528 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability. MNPR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MNPR has reported negative net income.
  • MNPR had a negative operating cash flow in the past year.
  • In the past 5 years MNPR always reported negative net income.
  • MNPR had a negative operating cash flow in each of the past 5 years.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • MNPR's Return On Assets of -13.48% is amongst the best of the industry. MNPR outperforms 81.44% of its industry peers.
  • With an excellent Return On Equity value of -13.73%, MNPR belongs to the best of the industry, outperforming 86.55% of the companies in the same industry.
Industry RankSector Rank
ROA -13.48%
ROE -13.73%
ROIC N/A
ROA(3y)-73.47%
ROA(5y)-60.42%
ROE(3y)-94.55%
ROE(5y)-74.37%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MNPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, MNPR has more shares outstanding
  • The number of shares outstanding for MNPR has been reduced compared to 5 years ago.
  • MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • MNPR has an Altman-Z score of 105.55. This indicates that MNPR is financially healthy and has little risk of bankruptcy at the moment.
  • MNPR has a better Altman-Z score (105.55) than 99.05% of its industry peers.
  • MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 105.55
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • MNPR has a Current Ratio of 56.10. This indicates that MNPR is financially healthy and has no problem in meeting its short term obligations.
  • MNPR's Current ratio of 56.10 is amongst the best of the industry. MNPR outperforms 99.62% of its industry peers.
  • MNPR has a Quick Ratio of 56.10. This indicates that MNPR is financially healthy and has no problem in meeting its short term obligations.
  • MNPR has a better Quick ratio (56.10) than 99.62% of its industry peers.
Industry RankSector Rank
Current Ratio 56.1
Quick Ratio 56.1
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

  • MNPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -101.02%.
EPS 1Y (TTM)-101.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MNPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.05% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.66%
EPS Next 2Y4.34%
EPS Next 3Y5.75%
EPS Next 5Y12.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MNPR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.34%
EPS Next 3Y5.75%

More info and screens

0

5. Dividend

5.1 Amount

  • MNPR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (1/14/2026, 8:00:01 PM)

After market: 69.6 0 (0%)

69.6

+2.56 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners65.05%
Inst Owner Change0%
Ins Owners4.78%
Ins Owner Change-110.65%
Market Cap464.93M
Revenue(TTM)N/A
Net Income(TTM)-19.44M
Analysts84.21
Price Target114.01 (63.81%)
Short Float %16.17%
Short Ratio4.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.93%
Min EPS beat(2)-9.44%
Max EPS beat(2)27.3%
EPS beat(4)2
Avg EPS beat(4)-119.71%
Min EPS beat(4)-541.92%
Max EPS beat(4)45.21%
EPS beat(8)5
Avg EPS beat(8)-52.2%
EPS beat(12)8
Avg EPS beat(12)-31.46%
EPS beat(16)10
Avg EPS beat(16)-22.47%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.14%
EPS NY rev (1m)0%
EPS NY rev (3m)4.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.28
P/tB 3.28
EV/EBITDA N/A
EPS(TTM)-3.96
EYN/A
EPS(NY)-3.75
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0
BVpS21.19
TBVpS21.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.48%
ROE -13.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.47%
ROA(5y)-60.42%
ROE(3y)-94.55%
ROE(5y)-74.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 56.1
Quick Ratio 56.1
Altman-Z 105.55
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.73%
EPS Next Y58.66%
EPS Next 2Y4.34%
EPS Next 3Y5.75%
EPS Next 5Y12.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-209.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-95.03%
EBIT Next 3Y-45.26%
EBIT Next 5YN/A
FCF growth 1Y-42.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.25%
OCF growth 3YN/A
OCF growth 5YN/A

MONOPAR THERAPEUTICS INC / MNPR FAQ

What is the ChartMill fundamental rating of MONOPAR THERAPEUTICS INC (MNPR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNPR.


What is the valuation status of MONOPAR THERAPEUTICS INC (MNPR) stock?

ChartMill assigns a valuation rating of 0 / 10 to MONOPAR THERAPEUTICS INC (MNPR). This can be considered as Overvalued.


What is the profitability of MNPR stock?

MONOPAR THERAPEUTICS INC (MNPR) has a profitability rating of 2 / 10.


Can you provide the financial health for MNPR stock?

The financial health rating of MONOPAR THERAPEUTICS INC (MNPR) is 9 / 10.


Can you provide the expected EPS growth for MNPR stock?

The Earnings per Share (EPS) of MONOPAR THERAPEUTICS INC (MNPR) is expected to grow by 58.66% in the next year.